Log in

OTCMKTS:ULURUluru Stock Price, Forecast & News

$0.50
0.00 (0.00 %)
(As of 05/26/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.50
Now: $0.50
$0.50
50-Day Range
$0.50
MA: $0.62
$0.80
52-Week Range
$0.01
Now: $0.50
$0.99
VolumeN/A
Average Volume11,059 shs
Market Capitalization$14.54 million
P/E RatioN/A
Dividend YieldN/A
Beta-2.52
ULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. and is headquartered in Addison, Texas.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.34 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ULUR
CUSIPN/A
Phone214-905-5145

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$720,000.00

Profitability

Miscellaneous

Employees2
Market Cap$14.54 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ULUR News and Ratings via Email

Sign-up to receive the latest news and ratings for ULUR and its competitors with MarketBeat's FREE daily newsletter.

Uluru (OTCMKTS:ULUR) Frequently Asked Questions

How has Uluru's stock been impacted by COVID-19 (Coronavirus)?

Uluru's stock was trading at $0.0255 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ULUR stock has increased by 1,860.8% and is now trading at $0.50. View which stocks have been most impacted by Coronavirus.

Has Uluru been receiving favorable news coverage?

News stories about ULUR stock have been trending extremely negative recently, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Uluru earned a daily sentiment score of -4.0 on InfoTrie's scale. They also assigned news coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news aboutUluru.

Who are some of Uluru's key competitors?

What other stocks do shareholders of Uluru own?

Who are Uluru's key executives?

Uluru's management team includes the following people:
  • Ms. Vaidehi A. Shah, Chairman & CEO (Age 42)
  • Mr. P. K Ramachandran, Chief Financial Officer (Age 65)

What is Uluru's stock symbol?

Uluru trades on the OTCMKTS under the ticker symbol "ULUR."

How do I buy shares of Uluru?

Shares of ULUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Uluru's stock price today?

One share of ULUR stock can currently be purchased for approximately $0.50.

How big of a company is Uluru?

Uluru has a market capitalization of $14.54 million and generates $720,000.00 in revenue each year. Uluru employs 2 workers across the globe.

What is Uluru's official website?

The official website for Uluru is www.uluruinc.com.

How can I contact Uluru?

Uluru's mailing address is 4410 BELTWAY DRIVE, ADDISON TX, 75001. The specialty pharmaceutical company can be reached via phone at 214-905-5145.

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.